323 related articles for article (PubMed ID: 28870104)
1. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.
Shin WJ; Seong BL
Expert Opin Drug Discov; 2017 Nov; 12(11):1139-1152. PubMed ID: 28870104
[TBL] [Abstract][Full Text] [Related]
2. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains.
Shin WJ; Seong BL
Expert Opin Drug Discov; 2019 Feb; 14(2):153-168. PubMed ID: 30585088
[TBL] [Abstract][Full Text] [Related]
3. Aprotinin and similar protease inhibitors as drugs against influenza.
Zhirnov OP; Klenk HD; Wright PF
Antiviral Res; 2011 Oct; 92(1):27-36. PubMed ID: 21802447
[TBL] [Abstract][Full Text] [Related]
4. The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases.
Kühn N; Bergmann S; Kösterke N; Lambertz RLO; Keppner A; van den Brand JMA; Pöhlmann S; Weiß S; Hummler E; Hatesuer B; Schughart K
J Virol; 2016 May; 90(9):4298-4307. PubMed ID: 26889029
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes.
Limburg H; Harbig A; Bestle D; Stein DA; Moulton HM; Jaeger J; Janga H; Hardes K; Koepke J; Schulte L; Koczulla AR; Schmeck B; Klenk HD; Böttcher-Friebertshäuser E
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391268
[TBL] [Abstract][Full Text] [Related]
6. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
McKimm-Breschkin JL; Fry AM
Antiviral Res; 2016 May; 129():21-38. PubMed ID: 26872862
[TBL] [Abstract][Full Text] [Related]
7. Influenza virus activating host proteases: Identification, localization and inhibitors as potential therapeutics.
Garten W; Braden C; Arendt A; Peitsch C; Baron J; Lu Y; Pawletko K; Hardes K; Steinmetzer T; Böttcher-Friebertshäuser E
Eur J Cell Biol; 2015; 94(7-9):375-83. PubMed ID: 26095298
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1.
Zmora P; Hoffmann M; Kollmus H; Moldenhauer AS; Danov O; Braun A; Winkler M; Schughart K; Pöhlmann S
J Biol Chem; 2018 Sep; 293(36):13863-13873. PubMed ID: 29976755
[TBL] [Abstract][Full Text] [Related]
9. Screening methods for influenza antiviral drug discovery.
Atkins C; Evans CW; White EL; Noah JW
Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
[TBL] [Abstract][Full Text] [Related]
10. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
Eichelberger MC; Hassantoufighi A; Wu M; Li M
Virol J; 2008 Sep; 5():109. PubMed ID: 18822145
[TBL] [Abstract][Full Text] [Related]
11. Investigational hemagglutinin-targeted influenza virus inhibitors.
Zeng LY; Yang J; Liu S
Expert Opin Investig Drugs; 2017 Jan; 26(1):63-73. PubMed ID: 27918208
[TBL] [Abstract][Full Text] [Related]
12. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
13. Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance.
Zhang J; Hu Y; Foley C; Wang Y; Musharrafieh R; Xu S; Zhang Y; Ma C; Hulme C; Wang J
Sci Rep; 2018 Mar; 8(1):4653. PubMed ID: 29545578
[TBL] [Abstract][Full Text] [Related]
14. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.
Meyer D; Sielaff F; Hammami M; Böttcher-Friebertshäuser E; Garten W; Steinmetzer T
Biochem J; 2013 Jun; 452(2):331-43. PubMed ID: 23527573
[TBL] [Abstract][Full Text] [Related]
15. Recent progress and challenges in the discovery of new neuraminidase inhibitors.
Chamni S; De-Eknamkul W
Expert Opin Ther Pat; 2013 Apr; 23(4):409-23. PubMed ID: 23369206
[TBL] [Abstract][Full Text] [Related]
16. Optimization of Ketobenzothiazole-Based Type II Transmembrane Serine Protease Inhibitors to Block H1N1 Influenza Virus Replication.
Colombo É; Désilets A; Hassanzadeh M; Lemieux G; Marois I; Cliche D; Delbrouck JA; Murza A; Jean F; Marsault E; Richter MV; Leduc R; Boudreault PL
ChemMedChem; 2024 Jan; 19(2):e202300458. PubMed ID: 37864572
[TBL] [Abstract][Full Text] [Related]
17. Perspective of Use of Antiviral Peptides against Influenza Virus.
Skalickova S; Heger Z; Krejcova L; Pekarik V; Bastl K; Janda J; Kostolansky F; Vareckova E; Zitka O; Adam V; Kizek R
Viruses; 2015 Oct; 7(10):5428-42. PubMed ID: 26492266
[TBL] [Abstract][Full Text] [Related]
18. DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry.
Zmora P; Blazejewska P; Moldenhauer AS; Welsch K; Nehlmeier I; Wu Q; Schneider H; Pöhlmann S; Bertram S
J Virol; 2014 Oct; 88(20):12087-97. PubMed ID: 25122802
[TBL] [Abstract][Full Text] [Related]
19. Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza.
Monod A; Swale C; Tarus B; Tissot A; Delmas B; Ruigrok RW; Crépin T; Slama-Schwok A
Expert Opin Drug Discov; 2015 Apr; 10(4):345-71. PubMed ID: 25792362
[TBL] [Abstract][Full Text] [Related]
20. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses.
Wong JP; Christopher ME; Viswanathan S; Dai X; Salazar AM; Sun LQ; Wang M
Curr Pharm Des; 2009; 15(11):1269-74. PubMed ID: 19355966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
